Showing 71-75 of 143 news & articles:
Validation of a machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritis

Published: October 29, 2021 Read the Full Article >> Objective: Disease activity measures, such as the Clinical Disease Activity Index (CDAI), are important tools for informing treatment decisions and monitoring patient outcomes in rheumatoid arthritis (RA). Yet, documentation of CDAI scores in electronic medical records and other real-world data sources is inconsistent, making it challenging[…]

Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice

Published: August 13, 2021 Read the Full Publication >> Background: Lung cancer is the leading cause of cancer-related death in the United States and globally, andmany questions exist about treatment options. Harmonizing data across registries and other data collection efforts would yield a robust data infrastructure to help address many research questions. The purpose of[…]

Using Real-World Data to Understand Patient Journeys in Dermatology

Listen to OM1’s podcast episode on the Medical Affairs Professional Society (MAPS) “Elevate” podcast series. Dr. Stefan Weiss is discussing ways to transform the way we conduct safety studies — relying more on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety. Moving away from cumbersome and[…]

OM1 Aims To Improve Healthcare Outcomes Through Big Data And AI

Forbes Publish Date: Nov 22, 2022 Harvard trained surgeon and big data entrepreneur Dr. Richard Gliklich has been working to improve the management of chronic conditions by organising, analysing and applying health outcomes data since 1999. Currently he is the founder and CEO of OM1 (pronounced Ohm-one). The company is a health outcomes and registries[…]

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

Springer Link Publish Date: November 4, 2022 Read the Full Article >>   Abstract Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical[…]

1 … 13 14 15 16 17 … 29